| HIV Infections
Stribild vs Cabenuva
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Stribild vs Cabenuva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCabenuva has a higher rate of injection site reactions vs Stribild based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cabenuva but not Stribild, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stribild
Cabenuva
At A Glance
Oral
Once daily
Integrase inhibitor + CYP3A inhibitor + nucleoside/nucleotide analog reverse transcriptase inhibitors
IM injection (gluteal)
Every 4 weeks or every 8 weeks
INSTI + NNRTI combination
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections One tablet (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg) taken orally once daily with food in adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance >=70 mL/min.
HIV Infections (Monthly Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in; Continuation: cabotegravir 400 mg IM + rilpivirine 600 mg IM every month thereafter. Separate gluteal injection sites required.
HIV Infections (Every 2-Month Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in, repeated 1 month later; Continuation: cabotegravir 600 mg IM + rilpivirine 900 mg IM every 2 months thereafter. Separate gluteal injection sites required.
Contraindications
- Coadministration with alfuzosin
- Coadministration with carbamazepine, phenobarbital, or phenytoin
- Coadministration with rifampin
- Coadministration with lurasidone or pimozide
- Coadministration with dihydroergotamine, ergotamine, or methylergonovine
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with lomitapide, lovastatin, or simvastatin
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with triazolam or orally administered midazolam
- Previous hypersensitivity reaction to cabotegravir or rilpivirine
- Carbamazepine, oxcarbazepine, phenobarbital, phenytoin (anticonvulsants)
- Rifabutin, rifampin, rifapentine (antimycobacterials)
- Dexamethasone (systemic, more than single dose)
- St. John's wort (Hypericum perforatum)
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B in coinfected patients, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Allergic reactions including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, increased amylase, abdominal pain, hepatic steatosis, hepatitis, increased liver enzymes, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria, asthenia
Most common (>=2%) Injection site reactions (pain/discomfort, nodules, induration, swelling, erythema, pruritus, bruising/discoloration, warmth, hematoma), pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash
Serious Hypersensitivity reactions including angioedema and urticaria, hepatotoxicity, depression and suicidal ideation/attempt, severe skin reactions including DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis
Postmarketing Hypersensitivity reactions, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis
Pharmacology
STRIBILD is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor), cobicistat (a CYP3A inhibitor that boosts elvitegravir levels), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor).
Cabotegravir inhibits HIV integrase by binding to the active site and blocking the strand transfer step essential for HIV replication. Rilpivirine is an NNRTI that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stribild
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Cabenuva
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Stribild
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (3/8) · Qty limit (5/8)
Cabenuva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Stribild
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Cabenuva
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Cabenuva Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
StribildView full Stribild profile
CabenuvaView full Cabenuva profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.